Glurenorm

Glurenorm is an oral tablet that contains the second‑generation sulfonylurea gliquidone. It is marketed in the European Union as a prescription‑only medication for the management of type 2 diabetes mellitus. The tablet delivers gliquidone to stimulate insulin release from pancreatic β‑cells, helping to lower blood glucose levels. Glurenorm belongs to the therapeutic class of oral hypoglycemics and carries ATC code A10BB04 in clinical practice worldwide today.

Glurenorm is indicated for use in adults with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy or in combination with other antidiabetic agents such as metformin. - May be considered when sulfonylurea therapy is appropriate and patient has adequate renal function. - Helps reduce HbA1c levels as part of a comprehensive diabetes management plan. - Is prescribed when a second‑generation sulfonylurea is preferred over first‑generation agents.

The safety profile of Glurenorm includes both frequent, mild reactions and less common, potentially serious events.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed. - Nausea or gastrointestinal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as rash, itching, or swelling. - Hepatic dysfunction manifested by jaundice or elevated liver enzymes.

Before prescribing Glurenorm, clinicians should evaluate several patient‑specific factors to minimize risk.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Use with caution in elderly patients due to increased hypoglycemia risk. - Avoid in pregnancy; classified as category C and discontinue if pregnancy occurs. - Monitor blood glucose regularly to detect hypoglycemia early. - Review concomitant medications that may potentiate hypoglycemia. - Caution in patients with a history of cardiovascular disease. - Educate patients on recognizing and managing low blood sugar symptoms.

Glurenorm can interact with other drugs, affecting its efficacy or safety.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole) that increase gliquidone plasma levels. - Discontinuation of beta‑blockers without medical supervision, which can mask hypoglycemia signs.

Use with caution: - Co‑administration with thiazolidinediones, requiring close glucose monitoring. - Use alongside diuretics that may alter electrolyte balance and affect insulin release. - Combination with warfarin, as glycemic changes can influence anticoagulant control.